130 / 490
128
SCIENTIFIC PROGRAMME
| PROGRAMME AND EXHIBITION GUIDE
INTERDISCIPLINARY RADIOBIOLOGY
CLINICAL BRACHYTHERAPY PHYSICS
RTT
YOUNG
MONDAY 2 MAY 2016
11:05 > Modelling of secondary cancer risks
Speaker: U. Schneider (Switzerland)
SP-0437
11:25 > Clinical implications of secondary cancer risks in pediatric and adult
patients
Speaker: D. Hodgson (Canada)
SP-0438
Proffered Papers
RADIOBIOLOGY 4: MOLECULAR BIOMARKERS FOR PATIENT SELECTION
10:45 - 11:45 | LONDRA
Chair: C. West (UK)
Chair: M. De Jong (The Netherlands)
10:45 > Localization of p16 expression is an important factor to determine
radiotherapy response in HNSCC
R. Dok (Belgium), L. Abbasi Asbagh, E. Van Limbergen, A. Sablina,
S. Nuyts
OC-0439
10:55 > Impact of chemokine receptor CXCR4 and its ligand SDF1 expression
on loco-regional control in HNSCC
A. Menegakis (Germany), C. De Colle, D. Moennich, F. Fend, P.S. Mauz,
S. Welz, I. Tinhofer, V. Budach, E. Gkika, M. Stuschke, P. Balermpas,
C. Roedel, M. Avlar, A.L. Grosu, A. Abdollahi, J. Debus, C. Bayer, C. Belka,
S. Pigorsch, S.E. Combs, M. Krause, M. Baumann, D. Zips
OC-0440
11:05 > Genomic amplification of FancA in HNSCC: mechanisms of radioresis-
tance and clinical relevance
J. Hess (Germany), I. Gimenez Aznar, A. Michna, D. Klein, U. Schötz,
M. Orth, L. Schneider, H. Braselmann, L. Schüttrumpf, V. Jendrossek,
C. Belka, V. Zangen, K. Unger, H. Zitzelsberger, K. Lauber
OC-0441
11:15 > Does miR-210 predict benefit from hypoxia modification in BCON
randomised bladder cancer patients?
C. West (UK), J. Irlam-Jones, A. Eustance, H. Denley,
P. Hoskin, A. Choudhury
OC-0442
11:25 > Radiotherapy sensitivity in breast cancer is influenced by the DNA cyto-
sine deaminase APOBEC3B
P.N. Span (The Netherlands), A. Post, J.W.M. Martens, R.S. Harris
OC-0443